Anti-CGRP monoclonal antibodies: a breakthrough in the treatment of migraine

Abstract

To date, the prophylactic treatment of migraine has included only nonspecific drugs of various pharmacological groups: the beta-blockers propranolol and metoprolol, the anticonvulsants topiramate and valproic acid, the antidepressants amitriptyline and venlafaxine, candesartan, and Ona botulinum toxin A. As these drugs were developed for treatment of other diseases, their use was associated with adverse effects: decreased blood pressure, mental retardation, weight increase, and some others. CGRP is a neuropeptide that was regarded as the main biomarker of migraine as its level in this disease rise. The emergence of humanized monoclonal antibodies has opened up the possibility of blocking the action of CGRP and developing a new class of drugs that includes fremanezumab, erenumab, galcanezumab, and eptinezumab. Anti-CGRP monoclonal antibodies can be prescribed to patients with chronic and episodic migraine. The use of anti-CGRP monoclonal antibodies in clinical studies was associated with a small number of adverse effects, with severe adverse reactions being extremely rare.

Keywords: migraine, calcitonin gene-related peptide, CGRP, antibody

Abbreviations: CGRP, calcitonin gene-related peptide; CNS, central nervous system; RAMP1, receptor activity-modifying protein 1; K ATP, ATP-sensitive potassium channel; GI, gastrointestinal

Introduction

Patients with migraine, a primary headache disorder affecting 15% of the population, will soon have access to drugs of a new pharmacological class, monoclonal antibodies to calcitonin gene-related peptide (CGRP). To date, the prophylactic treatment of migraine has included only nonspecific drugs of various pharmacological groups: the beta-blockers propranolol and metoprolol, the anticonvulsants topiramate and valproic acid, the antidepressants amitriptyline and venlafaxine, candesartan, and Ona botulinum toxin A. As these drugs were developed for treatment of other diseases, their use was associated with adverse effects: decreased blood pressure, mental retardation, weight increase, and some others. Adverse effects significantly worsen compliance with prophylactic treatment of migraine that should last 6–12 months. Therefore, migraine is still one of the most maladaptive conditions, which, according to WHO data, is among the top ten diseases with regard to number of years of disability. An active search for biomarkers of migraine that would enable specific therapy of this disease has been going on for a few decades.

The CGRP system

The neuropeptide calcitonin gene-related peptide (CGRP) was discovered in 1982 and promoted the study of the trigeminovascular system and its role in the development of migraine. CGRP is synthesized in peripheral sensory neurons and some regions of the central nervous system (CNS). There are two forms of CGRP, α and β. α-CGRP consists of 37 amino acids, and is synthesized in neurons through tissue-specific mRNA splicing. β-CGRP is found in the gastrointestinal tract. Transcription begins at the CALCA gene located on chromosome 11. After synthesis, CGRP is transported by vesicles to the axon terminal. The release of calcitonin gene-related peptide is stimulated by capsaicin. Presynaptic neurons are located on trigeminal neurons, and regulate CGRP release. Activation of 5-HT1B, 5-HT1D, and 5-HT1F serotonin receptors (the target for triptans and ditans, specific agents used to relieve migraine attacks) inhibits the release of CGRP.

After release into the synaptic cleft, calcitonin gene-related peptide is degraded by metalloproteases. Amidation of the carboxyl terminus of the peptide protects it from decomposition, thus prolonging the half-life. This property allows CGRP to reach the receptor and exert its effects some distance from its release site in a process called volume transmission.

The CGRP receptor is a complex consisting of several proteins each of which is necessary for ligand specificity and function of the receptor itself. The central part of the receptor, G-protein, is the CGRP receptor proper (CALCR) belonging to the family of secretin receptors. To be able to bind CGRP, the receptor has to form a heterodimer with receptor activity-modifying protein 1 (RAMP1). The CGRP binding site is located between the CALCR and RAMP1 receptors. Therefore, CGRP can affect its receptor only when CALCR and RAMP1 receptors are co-expressed. Activation of the receptor results in an increase in intracellular cAMP levels, which triggers phosphorylation of various targets, such as potassium channels (KATP), extracellular signal-regulated kinases, and transcription factors, including CREB. In smooth muscle cells of cerebral blood vessels, CGRP-induced cAMP increase leads to vascular wall relaxation and dilatation of the vessel. There is also a second CGRP receptor, amylin receptor (AMY1). It consists of RAMP1 and the calcitonin receptor, and is also found in the trigeminal ganglion. The role of this type of receptor in the mechanisms of migraine and in its treatment is unknown.

An important specific feature of CGRP neurotransmission is desensitization of the receptor by agonists. When CGRP binds to the...
CALCRL receptor, the latter is quickly phosphorylated and internalized into endosomes from where it can soon return to the membrane. Chronic exposure to CGRP triggers the process of internalization with capture of the receptor by lysosomes and subsequent destruction.  

**CGRP and migraine**

The key role of trigeminal sensory fibres in the development of primary headaches was already known at the time when CGRP was discovered. Since CGRP is mainly found in trigeminal neurons, it was thought to play a role in the pathogenesis of migraine. Besides, calcitonin gene-related peptide acts as a potent vasodilator, perfectly fitting into the vascular theory of migraine that was commonly adopted at the time. In 1990, Goadsby et al. demonstrated that CGRP is the only neuropeptide whose levels are increased in migraine. Calcitonin gene-related peptide was regarded as a potential diagnostic biomarker of migraine; however, its instability and short half-life precluded development of an informative test. Intravenous administration of CGRP in patients with migraine triggers a migraine attack, which allowed modeling of the disease. Finally, CGRP receptor antagonists, gepants, were synthesized and allowed effective relief of migraine attacks. A new class of drugs that includes anti-CGRP receptor monoclonal antibodies has opened up the possibility of blocking the action of CGRP in tissues.

**Anti-CGRP monoclonal antibodies**

Antibody drugs are the mainstream in the development of novel medicines, which is due to:

a. Very high specificity.

b. Optimal pharmacokinetic characteristics that allow drug administration once in 2–5 weeks.

c. Significantly better (compared with small molecules) spectrum of adverse effects, including hepatotoxicity, nephro-, cardio-, and neurotoxicity (except where due to direct effects on the target).

d. Greater opportunities for protection of intellectual property, as antibodies are difficult to “copy”.

**Efficacy of anti-CGRP monoclonal antibodies**

The first anti-CGRP monoclonal antibodies were synthesized after the discovery of the peptide in 1982, but these were used for diagnostic purposes in liquid chromatography and immunohistochemistry to study CGRP in tissues. The emergence of humanized monoclonal antibodies has opened up the possibility of blocking the action of CGRP and developing a new class of drugs that includes fremanezumab, galcanezumab, and eptinezumab. The development of anti-CGRP receptor monoclonal antibodies also provided a new approach to blocking the receptor. Erenumab is a human monoclonal antibody to the extracellular domains of CALCRL and RAMP1. Fremanezumab, galcanezumab, and erenumab are available for subcutaneous injection, and eptinezumab for intravenous infusion. The maximum serum concentration (Cmax) of the subcutaneous dosage forms is 4–13 days, while the Cmax of the intravenous eptinezumab is achieved on the day of administration. The short time to maximum concentration results in quick onset of action of the drugs. The elimination half-life is in the range of 25–32 days, so the drugs can be given once a month. Monoclonal antibodies are difficult to “copy” and greater opportunities for protection of intellectual property, as antibodies are difficult to “copy”.

All drugs based on monoclonal antibodies to CGRP or to its receptor have shown their efficacy in both episodic and chronic migraine, decreasing the frequency of both days of headache and days of migraine. In the STRIVE trial, 995 patients with episodic migraine were administered erenumab 70mg, erenumab 140mg, or placebo once monthly for 6 months. A 50% or greater reduction in migraine days at treatment months 4–6 was observed in 43.3% of patients treated with erenumab 70mg, in 50% of subjects in the erenumab 140mg arm, and in 26.6% of placebo-treated patients (p<0.001 for comparisons between each of the dose levels and placebo). The LIBERTY trial evaluated the efficacy of erenumab in patients with episodic migraine after failure of one or two drugs for the prevention of migraine. In this patient population, a 50% or greater reduction in migraine days was observed in 30.3% of patients treated with erenumab 140 mg and in 13.7% of placebo-treated subjects (p=0.002).

Eptinezumab was investigated in two studies, PROMISE 1 (episodic migraine) and PROMISE 2 (chronic migraine). In the PROMISE 1 protocol, patients received eptinezumab 30 mg, eptinezumab 100 mg, eptinezumab 300 mg, or placebo. A 50% or greater reduction in migraine days at treatment week 12 was observed in 50.2% of patients administered eptinezumab 30 mg (p=0.006), 49.8% of subjects in the eptinezumab 100 mg group (p=0.009), and 56.3% of patients receiving eptinezumab 300 mg.

HALO was the pivotal efficacy and safety study of fremanezumab in episodic and chronic migraine. Subjects with episodic migraine were administered fremanezumab 675 mg quarterly or fremanezumab 225 mg monthly or placebo. A 50% or greater reduction in migraine days was observed in 44.4% of patients treated with quarterly fremanezumab, in 47.7% of patients given monthly fremanezumab, and in 27.9% of placebo-treated patients (p<0.001 for comparisons between each of the dose levels and placebo). In the same study, patients with chronic migraine were given fremanezumab 675 mg quarterly and 225 mg at weeks 4 and 8, fremanezumab 675 mg monthly and placebo at weeks 4 and 8, or placebo. A 50% or greater reduction in migraine days was observed in 38% of patients treated with quarterly fremanezumab, in 41% of subjects given monthly fremanezumab, and in 18% of placebo-treated patients (p<0.001 for comparisons between each of the dose levels and placebo).

The efficacy of galcanezumab 120 mg and 240 mg versus placebo in patients with episodic or chronic migraine was assessed in the EVOLVE-1 and REGAIN studies. In episodic migraine, a 50% or greater reduction in migraine days at 6 months was observed in 62.3% of patients treated with galcanezumab 120 mg, in 62.3% of subjects given galcanezumab 240 mg, and in 42.5% of placebo-treated patients (p<0.001 for comparisons between each of the dose levels and placebo).

New efficacy endpoints, proportions of patients with 75% and 100% reductions in migraine days, were used for the first time in anti-CGRP studies. Clinical studies have been conducted with the following doses: 120 mg and 240 mg for episodic migraine, and 150 mg and 300 mg for chronic migraine.

**Practical aspects of the use of anti-CGRP monoclonal antibodies**

Anti-CGRP monoclonal antibodies can be prescribed to patients with chronic and episodic migraine. These drugs are mostly indicated for patients with pre-chronic migraine (8–14 days of migraine a month), as well as for patients with chronic migraine or episodic migraine with an average frequency of attacks (4–7 days of migraine a month). These agents should be considered for patients who cannot be administered standard therapy due to comorbidities, adverse effects
and low compliance.\textsuperscript{23} Monoclonal antibodies can prove effective after failure of one or two standard preventive migraine drugs.\textsuperscript{26}

The switch from standard therapy to treatment with monoclonal antibodies has some specific aspects. It is recommended to discontinue standard therapy before initiating antibodies in patients with episodic migraine. In chronic migraine or episodic migraine in a patient with a history of chronic migraine, anti-CGRP antibodies should be administered without discontinuing standard therapy. After that, once an effect has been achieved, standard therapy may be discontinued on an individual basis. The recommended duration of monoclonal antibody therapy is 6–12 months. In the presence of concurrent medication-overuse headache, monoclonal antibodies may be started either before or after detoxification. The main contraindications to the use of monoclonal antibodies are pregnancy and lactation; alcohol dependence and other types of dependences; relevant cardiac and cerebrovascular disorders; severe psychiatric disorders.\textsuperscript{23}

**Safety issues associated with the use of anti-CGRP monoclonal antibodies**

**Safety of the antibody platform of anti-CGRP drugs**

Hazards associated with the use of monoclonal antibodies may be due to specific effects on the target (see below) or abnormal response of the immune system. The latter may vary in severity from mild reactions of chills and fever to a potentially fatal cytokine storm. Other disadvantages of antibody drugs include their potential immunogenicity (formation of anti-drug antibodies potentially leading to decreasing efficacy in long-term use) and high cost of manufacturing. Both immunogenicity and the risk of abnormal immune response depend on the type of the antibody. Apparently, the risk is highest with mouse antibodies and lowest with human ones (which are usually more expensive to manufacture). Chimeric/humanized monoclonal antibodies are between the two extremes in this regard.\textsuperscript{27}

The IgG\textsubscript{1} subclass that the antibody belongs to is important as well: IgG\textsubscript{1} is significantly more likely to activate the complement system (which is undesirable in the treatment of migraine) than IgG4 and IgG\textsubscript{2}.\textsuperscript{28} On the other hand, IgG2 has the lowest potential antibody-dependent cell-mediated cytotoxicity, so this antibody class is most suitable for the manufacture of drugs for the treatment of migraine.

Based on the properties of the antibodies in question, one can assume that the humanized antibody fremanezumab and the human antibody erenumab, both of the IgG\textsubscript{2} subclass, can have the best safety profile and the lowest immunogenicity.\textsuperscript{29} This was confirmed by results of Phase II studies in which the frequency of immunogenicity reactions was found to be 1% for fremanezumab,\textsuperscript{30} 6% for erenumab,\textsuperscript{31} 12% for eptinezumab\textsuperscript{29} and up to 30% for galcanezumab. The study’s authors underline that the development of autoantibodies to galcanezumab did not result in any changes in blood concentrations of the drug or CGRP in the Phase II studies.\textsuperscript{30}

Drugs with lower risk of immunogenicity may be potentially preferable for patients with chronic migraine who may require longer use of anti-CGRP monoclonal antibodies.

It is essential to note that anti-CGRP monoclonal antibodies exhibit no impact on the central nervous system, as their high molecular weight makes them unable to cross the blood-brain barrier.\textsuperscript{4}

**General safety considerations associated with the use of anti-CGRP monoclonal antibodies**

The spectrum of adverse effects of anti-CGRP monoclonal antibodies is presented in Table 1.\textsuperscript{11}

<table>
<thead>
<tr>
<th>Drug</th>
<th>Fremanezumab</th>
<th>Erenumab</th>
<th>Galcanezumab</th>
<th>Eptinezumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common adverse reactions (incidence 1–10%)</td>
<td>Injection site reactions (up to 45%)</td>
<td>Injection site reactions (3–6%)</td>
<td>Constipation</td>
<td>Injection site reactions (18%)</td>
</tr>
</tbody>
</table>

Hypersensitivity reactions, such as rashes, angioneurotic oedema, and anaphylaxis, were also observed with all anti-CGRP MAs; their occurrence did not exceed that with other antibodies. Other adverse reactions identified during phase III CTs included nasopharyngitis and upper respiratory tract infections, urinary tract infection, dizziness, nausea, and arthralgia. The frequency of these adverse effects was comparable to the placebo arm. As eptinezumab was administered intravenously, no complications associated with subcutaneous administration were detected. Reactions at the injection site were evaluated in the studies in different ways; either all reactions were evaluated as one adverse event, or pain at the injection site, redness, infiltration, etc. were reported separately. Regardless of the method of evaluation, there was no difference with placebo.

The use of anti-CGRP monoclonal antibodies in clinical studies was generally associated with a small number of adverse effects, with severe adverse reactions being extremely rare. Below we will discuss safety issues associated with the specific inhibition of the CGRP system resulting from binding of therapeutic antibodies to the ligand or CGRP receptor.

**Gastrointestinal safety of anti-CGRP monoclonal antibodies**

The gastrointestinal (GI) tract has massive CGRPergic innervation. Its functions include regulation of gastrointestinal motility and protection of the mucous membrane from deleterious factors.\textsuperscript{22} In animal experiments, exposure to anti-CGRP monoclonal antibodies resulted in pronounced damage to the gastrointestinal mucous lining.\textsuperscript{33} Analysis of available clinical study results does not reveal any increase in the incidence of gastrointestinal adverse effects during treatment with anti-CGRP monoclonal antibodies, as compared with placebo. In particular, in the Phase III study of erenumab, ARISE, constipation was observed in 1.4% of erenumab-treated patients and in 2.1% subjects of the placebo group.\textsuperscript{34} According to Medscape data, constipation can occur in 3% of patients treated with erenumab medscape.com.

**Table 1** The most frequent adverse effects and adverse reactions reported during Phase II and III clinical trials (CTs) of anti-CGRP MAs

Cardiovascular safety of anti-CGRP monoclonal antibodies

CGRP plays a considerable role in the regulation of cardiovascular function, both in the central and peripheral nervous system and directly at the level of the heart and vessels. CRG receptors are expressed in peripheral arteries and the heart; besides, they are innervated by CGRPeric nerve fibres.

To date, experimental studies have yielded the following aspects of the effects of CGRP and its agonists on the cardiovascular system:

1. CGRP is a potent vasodilator, and exerts positive inotropic and chronotropic effects.;
2. CGRP gene knockout mice used in various hypertension models demonstrated significantly elevated blood pressure levels and more profound involvement of the target organs of hypertension compared with control animals;
3. Use of CGRP in a rat acute cerebral artery occlusion model was associated with less severe cerebral oedema;
4. Use of a slow-release system to deliver CGRP into the cerebrospinal fluid in a monkey subarachnoid haemorrhage model was associated with relieved vascular spasm. Similarly, administration of CGRP in patients with subarachnoid haemorrhage was associated with decreased severity of vascular spasm;
5. In biological models of myocardial infarction, CGRP decreased the volume of ischaemic myocardium and prevented the development of life-threatening arrhythmias.
6. Recently developed CGRP analogues demonstrated an antihypertensive effect, prevented pathological myocardial remodeling, and stimulated angiogenesis in biological models of hypertension and heart failure;
7. Use of CGRP in patients with congestive heart failure resulted in improved pumping capacity of the heart.

These experiments, as well as a number of others that are not mentioned in this paper, allow a conclusion that CGRP has cardioprotective and vasoprotective properties. Accordingly, the initially cautious use of anti-CGRP monoclonal antibodies was due to the risk of vasoconstriction, which in turn can elevate blood pressure and induce cerebral and myocardial ischaemia.

As a result, a programme was started to study the effects of CGRP antagonists on the cardiovascular system. In the overwhelming majority of experiments in biological models, use of CGRP antagonists did not affect haemodynamic parameters and had no effect on the severity of ischaemia in arterial occlusion. A study in a pithed rat model found that the CGRP antagonist olcegepant enhanced sympathetic adrenergic effects, which resulted in elevated blood pressure. Administration of CGRP antagonists in healthy volunteers did not increase blood pressure or have any other negative consequences either.

The most important clinical trial data were obtained for anti-CGRP monoclonal antibodies in Phase II and III studies that included office blood pressure monitoring and ECG recording. None of the studies, including a long-term follow-up (for more than 1.5 years), has yet been able to demonstrate any negative effect of anti-CGRP monoclonal antibodies on the cardiovascular system. It should be noted that the clinical studies of anti-CGRP monoclonal antibodies mainly recruited female patients at very low risk of cardiovascular events. To study the effects of these drugs in patients at high risk, erenumab was investigated in a separate double-blind, placebo-controlled, randomized study that enrolled 90 subjects with stable angina, including patients after acute myocardial infarction. A stress test revealed that erenumab 140mg i.v. had no effect on physical exercise tolerance or development of myocardial ischaemia. It was concluded that CGRP receptor blockade is safe for the cardiovascular system. The authors underlined that erenumab blocks only the canonical CGRP receptor without exerting any effect on the binding of CGRP to the amylase 1 receptor for which the former shows high affinity. These data are consistent with results that were obtained in a study of telagepant in patients with stable angina pectoris. The use of telagepant did not result in myocardial ischaemia, as revealed by a stress test, either. Therefore, the available data imply a rather good medium-term cardiovascular safety profile of anti-CGRP monoclonal antibodies in a typical population of migraine patients.

Further steps in the study of the cardiovascular safety of anti-CGRP monoclonal antibodies

Notwithstanding the promising results of a single study of erenumab in patients with stable ischaemic heart disease, the question of the safety of anti-CGRP monoclonal antibodies in patients at high risk of cardiovascular complications, particularly in the long term, is still open to debate. Currently these agents are contraindicated in patients with serious cardiovascular diseases. It is advisable to include 24-hour blood pressure monitoring in the protocols of new large-scale studies of CGPR inhibitors. In small-scale studies that enroll patients with heart disease, cardiac MRI with myocardial perfusion assessment and analysis of biomarkers (such as ultra-high sensitivity troponin and NT-pro-BNP) are the best tools to clearly demonstrate the absence of cardiac toxicity. The role of endothelial dysfunction in the pathogenesis of migraine and the influence of anti-CGRP monoclonal antibodies are not clearly understood yet, which warrants endothelial function studies in migraine patients treated with these drugs.

Acknowledgments

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The author declares no conflict of interest.

Funding

None.

References


